

REMARKS

By this Office Action, the Examiner has required restriction to one of the following inventions under 35 U.S.C. §121:

Group I. Claim(s) 1-4, 7-10 and 12, drawn to a method of screening an agent.

Group II. Claim(s) 24-32, drawn to a method of making a polypeptide.

Group III. Claim(s) 33-34, drawn to a method of making a plurality of polyribonucleotide sequences.

Group IV. Claim 35, drawn to a composition comprising an isolated nucleic acid sequence which encodes a polypeptide having sequence and/or structural homology to an mRNA interferase or a functional fragment thereof, an expression vector, a transgenic animal, and an isolated amino acid sequence and a kit.


Responsive to the Requirement for restriction, Applicants elect to prosecute the invention of Group II, without traverse, Claims 24-32, which are drawn to a method of making a polypeptide.

Responsive to the requirement for election of a species directed to one type of method, Applicant elects the method of claim 25 (wherein the mRNA recognition sequence is an Adenine-Cytosine-Adenine (ACA) sequence and the mRNA interferase is MazF comprising SEQ ID NO: 2. The elected species particularly reads on claims 25, 27, and 32 of elected Group II. Claims 26 and 31 of Group II are viewed as generic and thus, are believed to remain under consideration.

No additional fees are believed to be necessitated by the foregoing Response. However, should this be erroneous, authorization is hereby given to charge Deposit Account No. 11-1153 for any underpayment, or credit any overages.

In view of the above, an early action on the merits of the Claims is courteously solicited.

Respectfully submitted,



Sarah J. Fashena, Ph.D.
Agent for Applicant(s)
Registration No. 57,600

KLAUBER & JACKSON, LLC
411 Hackensack Avenue
Hackensack, New Jersey 07601
(201) 487-5800
Date: August 6, 2009